# Long-term Safety and Efficacy of ESK-001 in Moderate to Severe Plaque Psoriasis

> **NCT06846541** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Alumis Inc** · enrollment: 1680 (estimated)

## Conditions studied

- Plaque Psoriasis
- Psoriasis (PsO)
- Psoriasis
- Moderate Psoriasis
- Severe Psoriasis

## Interventions

- **DRUG:** Open-Label Envudeucitinib
- **DRUG:** Blinded Envudeucitinib
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06846541
- **Lead sponsor:** Alumis Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2025-01-08
- **Primary completion:** 2028-11
- **Final completion:** 2028-11
- **Target enrollment:** 1680 (ESTIMATED)
- **Last updated:** 2026-04-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06846541

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06846541, "Long-term Safety and Efficacy of ESK-001 in Moderate to Severe Plaque Psoriasis". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT06846541. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*